BEAM
Price
$23.47
Change
-$1.26 (-5.10%)
Updated
Oct 16 closing price
Capitalization
2.5B
23 days until earnings call
Intraday BUY SELL Signals
RYTM
Price
$86.17
Change
-$1.80 (-2.05%)
Updated
Oct 16 closing price
Capitalization
6.79B
24 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs RYTM

BEAM vs RYTM Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BEAM vs. RYTM commentary
Oct 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and RYTM is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BEAM with price predictions
Oct 16, 2026

Momentum Indicator for BEAM turns negative, indicating new downward trend

BEAM saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 79 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 50-day moving average for BEAM moved below the 200-day moving average on September 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for BEAM entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BEAM's RSI Indicator exited the oversold zone, 23 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for BEAM just turned positive on September 29, 2026. Looking at past instances where BEAM's MACD turned positive, the stock continued to rise in 42 of 53 cases over the following month. The odds of a continued upward trend are 79%.

Following a +5.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in 198 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.345) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (15.314) is also within normal values, averaging (437.542).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. BEAM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for RYTM with price predictions
Oct 16, 2026

RYTM's RSI Indicator descends into oversold zone

The RSI Indicator for RYTM moved into overbought territory on October 16, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where RYTM advanced for three days, in 237 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

RYTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RYTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.

The Aroon Indicator for RYTM entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 25 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. RYTM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (65.789) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (27.548) is also within normal values, averaging (437.542).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
BEAM vs RYTM: Fundamental Ratings
BEAM
RYTM
OUTLOOK RATING
1..100
8372
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
81
Overvalued
PROFIT vs RISK RATING
1..100
10025
SMR RATING
1..100
92100
PRICE GROWTH RATING
1..100
5972
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (26) in the null industry is somewhat better than the same rating for RYTM (81) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than RYTM’s over the last 12 months.

RYTM's Profit vs Risk Rating (25) in the Biotechnology industry is significantly better than the same rating for BEAM (100) in the null industry. This means that RYTM’s stock grew significantly faster than BEAM’s over the last 12 months.

BEAM's SMR Rating (92) in the null industry is in the same range as RYTM (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to RYTM’s over the last 12 months.

BEAM's Price Growth Rating (59) in the null industry is in the same range as RYTM (72) in the Biotechnology industry. This means that BEAM’s stock grew similarly to RYTM’s over the last 12 months.

BEAM's P/E Growth Rating (100) in the null industry is in the same range as RYTM (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to RYTM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMRYTM
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 13 days ago
77%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 5 days ago
73%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 17, 2026
Stock price -- (BEAM: $23.47 vs. RYTM: $86.17)
Brand notoriety: BEAM and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 95% vs. RYTM: 64%
Market capitalization -- BEAM: $2.5B vs. RYTM: $6.79B
BEAM [@Biotechnology] is valued at $2.5B. RYTM’s [@Biotechnology] market capitalization is $6.79B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green while RYTM’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • RYTM’s FA Score: 1 green, 4 red.
According to our system of comparison, BEAM is a better buy in the long-term than RYTM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 4 TA indicator(s) are bullish while RYTM’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 4 bullish, 4 bearish.
  • RYTM’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, RYTM is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а -8.68% price change this week, while RYTM (@Biotechnology) price change was -5.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.

Reported Earning Dates

BEAM is expected to report earnings on Nov 09, 2026.

RYTM is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Biotechnology (-10.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BEAM
Daily Signal:
Gain/Loss:
RYTM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
OUSA62.380.09
+0.14%
ALPS O'Shares U.S. Quality Dividend ETF (OUSA)
SPSB29.650.02
+0.07%
State Street SPDR Portfolio Short Term Corporate Bond ETF (SPSB)
UOCT42.51-0.21
-0.49%
Innovator U.S. Equity Ultra Buffer ETF - October (UOCT)
MAGC18.01-0.27
-1.47%
Roundhill China Magnificent Seven ETF (MAGC)
ONLN57.09-1.40
-2.40%
ProShares Online Retail ETF (ONLN)

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with SRRK. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then SRRK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
-2.05%
SRRK - RYTM
46%
Loosely correlated
-1.82%
VIR - RYTM
43%
Loosely correlated
-4.87%
BEAM - RYTM
41%
Loosely correlated
-5.10%
JBIO - RYTM
40%
Loosely correlated
-2.11%
GMAB - RYTM
40%
Loosely correlated
-2.17%
More